THE LONG DAWN

Dispatches / Cancer

The long siege of cancer

Immunotherapy alone may let some rectal cancer patients skip surgery, radiation and chemotherapy

For a few, the cure may no longer require the knife.

ApprovedRegulator decision

What happened

  • The FDA granted accelerated approval on 19 Oct 2026 to Jemperli (dostarlimab) alone for untreated stage II or III rectal cancer that is mismatch repair deficient (dMMR) or MSI-high, about 3% of these cancers.
  • In a phase 2 study of 154 patients, almost three-fourths had not needed surgery, radiotherapy or chemotherapy after a median follow-up of more than 2 years.
  • In an earlier 50-patient study at Memorial Sloan Kettering, none had detectable cancer after treatment, and of 27 followed at least 3 years, one had the cancer return.

What we don't know yet

  • Accelerated approval rests on interim results. Longer follow-up must show how often the cancer returns.
  • Immune side effects can be severe or fatal. It only applies to the small dMMR/MSI-H subgroup.

Primary sources

Not medical advice. This is a summary of published results, not a recommendation. Ask your own doctor whether any treatment or trial fits you. To look for trials near you, search ClinicalTrials.gov or the WHO trial registry portal.